Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7479MR)

This product GTTS-WQ7479MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7479MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1751MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ3265MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ11950MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ7719MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ445MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ8267MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ466MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ10243MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R603
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW